

Live-streaming from the UK and the Karolinska Universitetsjukhuset

**6th OF NOVEMBER 12:00-13:00**

From new data to daily clinical practice in Head and Neck Cancer:  
Treatment options in the first line unresectable recurrent and metastatic setting

By Professor Kevin Harrington, The Royal Marsden NHS Foundation

*Product information on pembrolizumab will occur based on current approved indications*

Welcome to a webinar on treatment options in Head and Neck Cancer by Prof. Kevin Harrington, investigator in key immunotherapy studies, and with moderation by Prof. Claes Mercke.



## Webcast agenda

Topic	Duration	Speaker
<b>MSD's footprint in Head and Neck cancer</b> <i>(product information about Keytruda)</i>	5 min	Tiago Pinheiro, Medical Advisor, MSD
<b>Introduction</b>	5 min	Prof. Dr. Claes Mercke, Professor/överläkare Karolinska Universitetssjukhuset
<b>An overview of treatment options in first-line uR/M HNSCC</b> <ul style="list-style-type: none"><li><i>Including chemotherapy, radiotherapy and immunotherapy (and updates from ASCO/ESMO)</i></li></ul>	25 min	Prof. Dr. Kevin Harrington, Clinical Oncologist at The Royal Marsden NHS Foundation
<b>Discussion and Q&amp;A</b> <ul style="list-style-type: none"><li><i>Patient cases</i></li><li><i>What is the clinical practice in the UK and what is the clinical practice in Sweden?</i></li><li><i>Which patient profile is most suitable for immunotherapy alone and in combination with chemotherapy? Reflections on ECOG PS, age, comorbidities, tumor location, quality of life, PD-L1 status, etc.</i></li></ul>	25 min	Prof. Dr. Kevin Harrington, Clinical Oncologist at The Royal Marsden NHS Foundation Chair: Prof. Dr. Claes Mercke, Professor/överläkare Karolinska Universitetssjukhuset

uR/M HNSCC = unresectable recurrent and metastatic Head and Neck Squamous Cell Carcinoma



## Attendance to this event is possible in two ways:



1. By registering at the webcast link below at an internet-enabled device;  
<https://event.on24.com/wcc/r/2509600/A0E4B1500DE213B78021B18B02AD3900>
2. In person, if your hospital is having a dedicated streaming site together with your fellow colleagues. If you're attending at a streaming site we would still appreciate that you register at the link above. If you're interested in having a dedicated streaming site at your hospital please contact [tiago.pinheiro1@merck.com](mailto:tiago.pinheiro1@merck.com).

### About the speaker

Professor Kevin Harrington (BSc MBBS MRCP FRCR FRCP PhD DIC) specialises in treating patients with head and neck cancer. In addition to expertise in the use of radiotherapy and chemoradiotherapy, he is an authority on drug treatment of relapsed and metastatic head and neck cancer. He is a Consultant Clinical Oncologist at The Royal Marsden NHS Foundation, a Professor in Biological Cancer Therapies at The Institute of Cancer Research (ICR) in the United Kingdom and Joint Head of the Division of Radiotherapy and Imaging at that same institute.



Professor Harrington has published more than 400 articles on cancer treatment and his work has been featured in newspaper and television reports. Much of Professor Harrington's laboratory work is immediately translated into clinical trials at The Royal Marsden, most often in patients with head and neck cancers and melanomas. He is an experienced investigator in key immunotherapy studies in the recurrent and metastatic head and neck cancer setting. Professor Harrington says that his focus is on conducting innovative laboratory research with a view to applying it in the clinical setting for "real patient benefit". Last but not least, his research team focuses on two main areas: the use of viruses as anti-cancer agents and the development of new drugs that improve the activity of radiation against cancer cells.

*MSD covers the cost of the lunch at the dedicated streaming sites in the presence of a MSD representative*



**MSD**

**INVENTING FOR LIFE**